P1247 - Outcomes Following Endoscopic Resection of Duodenal Neuroendocrine Tumors

Sarang Gupta, MD, Gurmun Brar, MD, Katina Zheng, MD, Shaheed Hakim, MD, Christopher Teshima, MD, PhD, Gary May, MD, Calvin Law, MD, MPH, Julie Hallet, MD, MSc, Jeffrey Mosko, MD, MSc
University of Toronto, Toronto, ON, Canada

Introduction: Duodenal neuroendocrine tumors (D-NET) are rare cancers derived from neuroendocrine cells of the duodenum. A steady increase in the incidence of these tumors has been observed. Current management strategies are guided by various tumor characteristics including size, grade, and depth of invasion. There exists conflicting evidence, however, on the rates of recurrence after positive resection margins (R1) following endoscopic resection. Thus, it remains uncertain whether complete endoscopic resection (R0) of these indolent tumors is clinically significant and whether follow-up endoscopic or surgical intervention is justified. Our aim is to characterize the management and clinical outcomes in patients undergoing endoscopic resection of D-NETs.

Methods: We conducted a retrospective, single-centre cohort study. Consecutive patients over the age of 18 who underwent endoscopic resection of histologically proven D-NETs between 2011 and 2020 were included. Data on patient, endoscopic, and tumor characteristics were collected through electronic chart review. Descriptive statistics were conducted for data analysis.

Results: A total of 47 D-NETs were endoscopically resected amongst 43 patients (Table I). Mean tumor size was 9.88 ± 6.86 mm. Conventional endoscopic mucosal resection (EMR) was performed most frequently (55%, n=26/47), followed by cap-assisted EMR (30%, n=14/47). Hybrid endoscopic submucosal dissection (ESD)/EMR was performed in one case. A total of two intra-procedural perforations occurred, both of which were successfully closed endoscopically. One patient with a peri-ampullary D-NET experienced significant intra-procedural bleeding requiring endoscopic intervention and endotracheal intubation resulting in a brief hospitalization. 57% of all resected D-NETs were followed at surveillance endoscopy 1 (SE1) at a median interval of 199 days (range, 84 to 830). R1 margins were found in 26 cases (55%), of which 16 were assessed at SE1. Of these, one patient was electively treated with APC and two were referred to surgery. Tumor recurrence occurred in two patients.

Discussion: D-NETs recur in less than 5% of patients at initial surveillance endoscopy following endoscopic resection. In spite of a high R1 resection rate, our study suggests that patients with these indolent tumors who have positive margins can be managed conservatively with surveillance endoscopy. Further investigation is warranted to determine the optimal duration and interval surveillance strategy for these patients.



Disclosures:


Sarang Gupta, MD, Gurmun Brar, MD, Katina Zheng, MD, Shaheed Hakim, MD, Christopher Teshima, MD, PhD, Gary May, MD, Calvin Law, MD, MPH, Julie Hallet, MD, MSc, Jeffrey Mosko, MD, MSc. P1247 - Outcomes Following Endoscopic Resection of Duodenal Neuroendocrine Tumors, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.